$2.88 -0.13 (-4.32%)

Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics, Inc. (CATX) is a biotech company focused on developing innovative radiopharmaceuticals for the diagnosis and treatment of cancer. The company aims to leverage targeted imaging and therapy solutions to improve patient outcomes through advanced nuclear medicine technologies.

🚫 Perspective Therapeutics, Inc. does not pay dividends

Company News

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds
Benzinga • Prnewswire • July 23, 2025

Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.

ONCYCUEVSTMALLO
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results
GlobeNewswire Inc. • Perspective Therapeutics • July 15, 2025

Perspective Therapeutics, a radiopharmaceutical company, will report its Q2 2025 financial results on August 13, 2025, focusing on advanced cancer treatments using alpha-emitting isotope 212Pb and developing complementary imaging diagnostics.

Wall Street Analysts Think Perspective Therapeutics (CATX) Could Surge 80.31%: Read This Before Placing a Bet - Zacks Investment Research
Zacks Investment Research • Zacks.Com • July 16, 2024

Wall Street analysts believe Perspective Therapeutics (CATX) stock could surge by 80.31% based on their price targets, but investors should be cautious as price targets can be unreliable indicators of future stock performance.